ArticleCurrent oncology (Toronto, Ont.)2025
Real-World Data to Assess the Proportion of Patients Admitted for Febrile Neutropenia That Could Be Considered at Low Risk: The Experience of the Centre Hospitalier Universitaire de Québec.
Article in Current oncology (Toronto, Ont.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development and clinical validation of a nursing risk prediction model for chemotherapy-induced febrile neutropenia in patients with cancer.Frontiers in cell and developmental biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Febrile neutropenia (FN) is a serious complication of chemotherapy that often leads to hospitalization in cancer patients. It is now well-established that carefully selected patients can be safely treated on an outpatient basis. The objective of this study was to assess the number and proportion of patients hospitalized for FN in a university hospital setting who would have met the low-risk criteria for FN, and whether these patients experienced favorable outcomes during hospitalization. We conducted a retrospective study of all patients admitted for FN at three hospitals in Quebec City between 1 January 2018 and 31 December 2019. Patients with leukemia and those who had undergone stem cell transplants were excluded. A retrospective chart review was performed to establish the Multinational Association for Supportive Care in Cancer (MASCC) score for each patient. Based on predefined criteria, we also determined whether the clinical course was favorable or unfavorable. A total of 177 hospitalizations met our inclusion criteria. We found that 101/177 (57.1%) of the hospitalized patients met the low-risk FN criteria according to their MASCC score. Among these, 74/177 (41.8%) met all the criteria for outpatient treatment. The majority of these patients had a favorable outcome (70/74, 94.6%). In contrast, among patients who did not meet the eligibility criteria for outpatient treatment, 44.7% (46/103) experienced favorable outcomes during their hospitalization. These data highlight the importance of patient selection for outpatient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.